Skip to main content

Advertisement

SpringerLink
Log in

Dermatomyositisspezifische Antikörper

Dermatomyositis-specific antibodies

  • Übersichten
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

Zusammenfassung

Hintergrund

Die idiopathischen inflammatorischen Myositiden sind chronische, systemische Autoimmunkrankheiten, die durch symmetrische, proximale Muskelschwäche charakterisiert sind. Die klinisch-pathologische Einteilung scheint heutzutage obsolet zu sein, deshalb ist eine immunserologische Klassifikation erstellt worden.

Fragestellung

Einer der wichtigsten Phänotypen der Myositiden ist die Dermatomyositis. In dieser Gruppe spielen die dermatomyositisspezifischen Autoantikörper eine bedeutende Rolle, die hier mithilfe der Fachliteratur dargestellt werden.

Material und Methoden

Nach dem Überblick der wichtigsten Informationen über Dermatomyositis wird nicht nur der seit Langem bekannten Autoantikörper (anti-Mi-2) vorgestellt, sondern auch kürzlich identifizierte Autoantikörper: anti-TIF1γ, anti-NXP2, anti-SAE und anti-MDA5. Im Mittelpunkt stehen die Häufigkeit dieser Autoantikörper, die verbundenen Symptome bei Erwachsenen und Jugendlichen sowie einige spezielle Relationen aus der Fachliteratur.

Ergebnisse

Alle Studien bestätigen, dass diese Autoantikörper v. a. bei Dermatomyositis nachweisbar sind. Aufgrund der aktuellsten Literatur sind die neu identifizierten Autoantikörper bei Jugendlichen mit Myositis häufiger, als die klassischen Autoantikörper (anti-Jo-1, anti-Mi-2, anti-SRP).

Schlussfolgerungen

Es ist sinnvoll, diese Autoantikörper nachzuweisen, um während des Krankheitsverlaufs die Symptome und Prognose besser abschätzen zu können.

Abstract

Background

Idiopathic inflammatory myopathies are chronic systemic autoimmune diseases characterized by symmetrical proximal muscle weakness. The clinicopathological subdivision nowadays appears to be obsolete which is why the immunoserological classification has been developed.

Objectives

Dermatomyositis represents one the most important subsets of idiopathic inflammatory myopathy and dermatomyositis-specific autoantibodies play a significant role in this subset. The aim of this article was to present these autoantibodies with the help of the literature.

Methods

This article presents the most important information about dermatomyositis including not only the classical anti-Mi-2 autoantibody but also the recently detected anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5 autoantibodies. The focus is on the frequency of these autoantibodies, the associated symptoms in adult and juvenile dermatomyositis cases and some special aspects from the literature.

Results

All of the studies confirmed that these autoantibodies are particularly detectable in dermatomyositis. The results from the literature have recently shown that the frequency of the autoantibodies detected in juvenile cases is higher than the frequency of traditional autoantibodies (e.g. anti-Jo-1, anti-Mi-2 and anti-SRP).

Conclusion

It is useful to detect these autoantibodies in order to be able to make a better assessment of the clinical symptoms and prognosis during the course of the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347

    Article  CAS  PubMed  Google Scholar 

  2. Dorph C, Lundberg IE (2002) Idiopathic inflammatory myopathies – myositis. Best Pract Res Clin Rheumatol 16:817–832

    Article  PubMed  Google Scholar 

  3. Kim S, Genth E, Krieg T, Hunzelmann N (2005) PM-Scl-Antikörper positive systemische Sklerodermie assoziiert mit Einschlüsskörper-Myositis. Z Rheumatol 64:499–502

    Article  CAS  PubMed  Google Scholar 

  4. Genth E, Mierau R (1995) Diagnostische Bedeutung Sklerodermie- und Myositis-assoziierter Autoantikörper. Z Rheumatol 54:39–49

    CAS  PubMed  Google Scholar 

  5. Brouwer R, Hengstman GJ, Vree Egberts W et al (2001) Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 60:116–123

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Sugie K, Tonomura Y, Ueno S (2012) Characterization of dermatomyositis with coexistence of anti-Jo-1 and anti-SRP antibodies. Intern Med 51:799–802

    Article  PubMed  Google Scholar 

  7. Tansley SL, Betteridge ZE, McHugh NJ (2013) The diagnostic utility of autoantibodies in adult and juvenile myositis. Curr Opin Rheumatol 25:772–777

    Article  CAS  PubMed  Google Scholar 

  8. Betteridge ZE, Gunawardena H, McHugh NJ (2011) Novel autoantibodies and clinical phenotypes in adult and juvenile myositis. Arthritis Res Ther 13:209

    Article  PubMed Central  PubMed  Google Scholar 

  9. Targoff IN (2000) Update on myositis-specific and myositis-associated autoantibodies. Curr Opin Rheumatol 12:475–481

    Article  CAS  PubMed  Google Scholar 

  10. Volc-Platzer B (2010) Update: Dermatomyositis. Hautarzt 61:69–78

    Article  CAS  PubMed  Google Scholar 

  11. Stanciu R, Guiquet M, Musset L et al (2012) Antisynthetase syndrome with anti-Jo1 antibodies in 48 patients: pulmonary involvement predicts disease-modifying antirheumatic drug use. J Rheumatol 39:1835–1839

    Article  PubMed  Google Scholar 

  12. Marie I, Josse S, Decaux O et al (2012) Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev 11:739–745

    Article  CAS  PubMed  Google Scholar 

  13. Labirua-Iturburu A, Selva-O’Callaghan A, Vincze M et al (2012) Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature. Medicine (Baltimore) 91:206–211

  14. Rigolet A, Musset L, Dubourg O et al (2012) Inflammatory myopathies with anti-Ku antibodies: a prognosis dependent on associated lung disease. Medicine (Baltimore) 91:95–102

  15. Liang C, Needham M (2011) Necrotizing autoimmune myopathy. Curr Opin Rheumatol 23:612–619

    Article  PubMed  Google Scholar 

  16. Allenbach Y, Drouot L, Rigolet A et al (2014) Anti-HMGCR autoantibodies in european patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore) 93:150–157

  17. Targoff IN, Reichlin M (1985) The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum 28:796–803

    Article  CAS  PubMed  Google Scholar 

  18. Love LA, Leff RL, Fraser DD et al (1991) A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 70:360–374

  19. Cruellas MG, Viana Vdos S, Levy-Neto M et al (2013) Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis. Clinics (Sao Paulo) 68:909–914

  20. Rider LG, Shah M, Mamyrova G et al (2013) The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 92:223–243

  21. Petri MH, Satoh M, Martin-Marquez BT et al (2013) Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara. Arthritis Res Ther 15:48

    Article  Google Scholar 

  22. Hamaguchi Y, Kuwana M, Hoshino K et al (2011) Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol 147:391–398

    Article  CAS  PubMed  Google Scholar 

  23. Selva-O’Callaghan A, Labrador-Horrillo M, Solans-Laque R et al (2006) Myositis-specific and myositis-associated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy. Arthritis Rheum 55:791–798

    Article  Google Scholar 

  24. Hengstman GJ, Vree Egberts WT, Seelig HP et al (2006) Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen. Ann Rheum Dis 65:242–245

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Labrador-Horrillo M, Martínez MA, Selva-O’Callaghan A et al (2012) Anti-TIF1γ antibodies (anti-p155) in adult patients with dermatomyositis: comparison of different diagnostic assays. Ann Rheum Dis 71:993–996

    Article  CAS  PubMed  Google Scholar 

  26. Fujimoto M (2013) Myositis-specific autoantibodies. Brain Nerve 65:449–460 (Article in Japanese)

    CAS  PubMed  Google Scholar 

  27. Valenzuela A, Chung L, Casciola-Rosen L et al (2014) Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis. JAMA Dermatol 150:724–729

    Article  PubMed Central  PubMed  Google Scholar 

  28. Betteridge ZE, Gunawardena H, Chinoy H et al (2009) Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann Rheum Dis 68:1621–1625

    Article  CAS  PubMed  Google Scholar 

  29. Ceribelli A, Fredi M, Taraborelli M et al (2014) Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis. Clin Exp Rheumatol (Epub ahead of print)

  30. Tansley S, Gunawardena H (2013) The evolving spectrum of polymyositis and dermatomyositis-moving towards clinicoserological syndromes: a critical review. Clin Rev Allergy Immunol 47(3):264–273

    Article  Google Scholar 

  31. Hamaguchi Y, Kuwana M, Hoshino K et al (2011) Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol 147:391–398

    Article  CAS  PubMed  Google Scholar 

  32. Fiorentino D, Chung L, Zwerner J et al (2011) The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 65:25–34

    Article  PubMed Central  PubMed  Google Scholar 

  33. Tansley SL, Betteridge ZE, Gunawardena H et al (2014) Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res Ther 16:R138

    Article  PubMed Central  PubMed  Google Scholar 

  34. Peixoto D, Costa J, Ferretti M et al (2013) New autoantibodies and their clinical associations in juvenile myositis – a systematic review. Acta Reumatol Port 38:234–241

    PubMed  Google Scholar 

  35. Bodoki L, Nagy-Vincze M, Griger Z et al (2014) Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort. Autoimmun Rev (Epub ahead of print)

  36. Szankai Z, Nagy-Vincze M, Bodoki L et al (2014) Risk factors for cancer in patients with myositis. Clinical, immunological characteristics and the role of the anti-p155/140 antibody. Orv Hetil 155:1437–1444 (Article in Hungarian)

    Article  PubMed  Google Scholar 

Download references

Einhaltungen ethischer Richtlinien

Interessenkonflikt. L. Bodoki, M. Nagy-Vincze, Z. Griger und K. Dankó geben an, dass kein Interessenkonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Danksagung

Die Autoren danken Frau Marianna Fodor, Frau Boglárka Ritter und Herrn Ronny Meyer für die Hilfe beim Erstellen des Manuskripts.

Author information

Authors and Affiliations

  1. Abteilung der klinischen Immunologie, Allgemeinmedizinische Fakultät, Universität von Debrecen, Móricz Zs. krt. 22., 4032, Debrecen, Ungarn

    L. Bodoki M.D., M. Nagy-Vincze, Z. Griger & K. Dankó

Authors
  1. L. Bodoki M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Nagy-Vincze
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Z. Griger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. Dankó
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. Bodoki M.D..

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bodoki, L., Nagy-Vincze, M., Griger, Z. et al. Dermatomyositisspezifische Antikörper. Z Rheumatol 74, 363–369 (2015). https://doi.org/10.1007/s00393-014-1524-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-014-1524-7

Schlüsselwörter

Keywords

Search

Navigation